Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC)
Status:
Terminated
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
Primary objectives :
- To investigate the safety and the tolerability of ATO by IV infusions to patients with
SLE,
- To determine the maximum tolerated dose of ATO.
Secondary objectives :
- Evaluation of the clinical and biological response of the SLE to ATO,
- Time of relapse in case of positive response,
- Determination of the efficacy,
- Pharmacokinetic study of ATO.